Clinical Trial Update: A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial evaluating an MMSET inhibitor for relapsed and refractory multiple myeloma. Recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• MMSET inhibitor

Snippet

Sponsor: K36 Therapeutics, Inc. | Conditions: Multiple Myeloma, Myeloma | Phase 1 | Status: RECRUITING